Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
URVOGELBIO PRIVATE LIMITED maintains a focused presence in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution is contained within 1 distinct art unit, indicating a specific technical focus for the company's current applications. The portfolio is managed by 1 distinct examiner, which simplifies the administrative oversight required for these filings. This focus allows the company to concentrate its legal resources on 1 point of contact at the USPTO.
BERHANE, SELAM is designated as the busiest examiner for the portfolio, currently handling 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the company's prosecution strategy is entirely dependent on the interactions within 1 channel. This structure allows for a direct and consistent approach to addressing the requirements of the USPTO for the pending matter. Practitioners can prioritize understanding the specific examination history of BERHANE, SELAM to optimize the outcome for this application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERHANE, SELAM | 1 | 59.4% | +57.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17912091 | BIOMARKER PANELS, SYSTEMS, AND METHODS FOR RISK STRATIFICATION OF A SUBJECT FOR ALZHEIMER'S DISEASE | BERHANE, SELAM | 114d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17912091 | BIOMARKER PANELS, SYSTEMS, AND METHODS FOR RISK STRATIFICATION OF A SUBJECT FOR ALZHEIMER'S DISEASE | BERHANE, SELAM | 114d overdue |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17912091 | BIOMARKER PANELS, SYSTEMS, AND METHODS FOR RISK STRATIFICATION OF A SUBJECT FOR ALZHEIMER'S DISEASE | BERHANE, SELAM | 1675 | §101§103§112 | Final Rejection | 114d overdue | Pending | Sep 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialURVOGELBIO PRIVATE LIMITED has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Selam Berhane has the most, with 1 of URVOGELBIO PRIVATE LIMITED's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.